Dedicated to your research needs.


Please enter subscribe form shortcode

Preclinical Research in Psychedelic Therapies

When it comes to developing psychedelic therapies, the transition from the discovery phase to the preclinical phase is a crucial step. This phase involves rigorous testing to evaluate the safety and efficacy of psychedelic drugs before they can be considered for human trials. In this second blog post in our 7-Part Series: Psychedelic Therapy Drug Development, we will explore the various aspects of preclinical efficacy testing for psychedelic therapies, including in vitro and in vivo studies, investigating mechanisms of action, safety and toxicology preclinical studies, as well as formulation and dosing considerations.

In vitro and In vivo Studies

Before moving into preclinical efficacy testing, researchers conduct in vitro studies to understand how psychedelic compounds interact with specific cellular targets. These studies involve testing the effects of the drug on isolated cells or tissues in a controlled laboratory setting. In vitro studies provide valuable insights into the potential mechanisms of action and help identify promising compounds for further investigation.

Following in vitro studies, researchers move on to in vivo studies, which involve testing the psychedelic compounds in animal models. These studies allow researchers to evaluate the drug’s pharmacokinetics, distribution, and potential therapeutic effects in a more complex biological system. In vivo studies help determine the appropriate dosage levels and potential side effects of the psychedelic drugs.

Preclinical Efficacy Assessments

Preclinical efficacy assessments aim to determine whether the psychedelic therapies have the desired therapeutic effects in animal models. These assessments involve conducting behavioral and cognitive tests to evaluate the drug’s impact on the target condition or symptom. For example, if the psychedelic therapy is intended for the treatment of depression, researchers may use animal models of depression to assess the drug’s antidepressant effects.

By measuring various behavioral and cognitive parameters, researchers can gauge the efficacy of the psychedelic therapy and make informed decisions about its potential for further development. Preclinical efficacy assessments provide crucial data to support the progression of promising psychedelic compounds into human clinical trials.

Investigating Mechanisms of Action

Understanding the mechanisms of action is essential for developing effective psychedelic therapies. During the preclinical phase, researchers investigate how psychedelic compounds interact with specific receptors or neural circuits in the brain. This knowledge helps in identifying the key targets and pathways involved in the therapeutic effects of the psychedelic drugs.

Investigating the mechanisms of action also aids in the selection of appropriate animal models and the design of relevant behavioral tests. By unraveling the underlying mechanisms, researchers can optimize the therapeutic potential of psychedelic therapies and develop more targeted and effective treatments.

Safety and Toxicology Studies

While assessing efficacy is crucial, ensuring the safety of psychedelic therapies is equally important. Preclinical safety and toxicology studies aim to identify potential adverse effects and determine the drug’s safety profile. These studies involve evaluating the drug’s potential toxicity, genotoxicity, carcinogenicity, and reproductive effects, among others.

By conducting comprehensive safety and toxicology studies, researchers can identify any potential risks associated with the psychedelic therapies and make informed decisions about their safety for human use. This step is crucial in ensuring the well-being of patients who may participate in future clinical trials.

Formulation and Dosing Considerations

During the preclinical phase, researchers also explore different formulation and dosing considerations for psychedelic therapies. Formulation considerations involve determining the most suitable delivery method for the drug, such as oral administration, injection, or inhalation. Researchers also explore different formulations to improve drug stability, bioavailability, and patient compliance.

Dosing considerations involve finding the optimal dose range that provides therapeutic effects while minimizing potential side effects. Researchers evaluate various dosing regimens in animal models to determine the safest and most effective dose for human trials.

Key Takeaways for the Preclinical Phase of Psychedelic Drug Development

The transition from the discovery phase to the preclinical phase is a critical step in the development of psychedelic therapies. Through in vitro and in vivo studies, preclinical efficacy assessments, investigations into mechanisms of action, safety and toxicology studies, and formulation and dosing considerations, researchers gather crucial data to support the advancement of psychedelic compounds into human trials. Careful and comprehensive preclinical testing is essential for ensuring the safety and efficacy of psychedelic therapies and paving the way for their potential use in treating various mental health conditions.

Learn More About the Drug Discovery to Market Journey for Psychedelics

  1. FDA Market Approval Process for Psychedelic Therapies
  2. Unveiling the Mysteries: Drug Discovery in Psychedelic Therapies
  3. Building the Foundation: Preclinical Research in Psychedelic Therapies
  4. Navigating the Regulatory Landscape: IND Application for Psychedelic Therapies
  5. First Steps Towards Healing: Phase 1 Clinical Trials in Psychedelic Therapies
  6. Evaluating Efficacy: Phase 2 Clinical Trials in Psychedelic Therapies
  7. The Final Hurdle: Phase 3 Clinical Trials in Psychedelic Therapies

Contact our team to learn more about our psychedelics CRO services for the preclinical phase of drug development.


  1. De Gregorio D, Aguilar-Valles A, Preller KH, et al. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. J Neurosci. 2021;41(5):891-900. doi:10.1523/JNEUROSCI.1659-20.2020.
  2. Murnane KS. The renaissance in psychedelic research: What do preclinical models have to offer. Prog Brain Res. 2018;242:25-67. doi:10.1016/bs.pbr.2018.08.003.
  3. Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ. Mescaline: The forgotten psychedelic. Neuropharmacology. 2023;222:109294. doi:10.1016/j.neuropharm.2022.109294.
  4. Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, Morgan CJA. Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology. 2018;142:72-82. doi:10.1016/j.neuropharm.2018.01.017.
Post Tags :